First-in-class treatment
RYBREVANT® is a bispecific antibody with an extracellular binding mechanism.1
3-Pronged MOA
RYBREVANT® is a bispecific antibody that binds to the extracellular domains of EGFR and MET, and acts with a 3-pronged approach1:
- Block ligand binding1
- Receptor degradation1
- Antibody-dependent cellular cytotoxicity and trogocytosis1
See how RYBREVANT® works
Watch this video about the MOA of RYBREVANT®, engineered to take on EGFR exon 20 insertion mutations1
The presence of EGFR and MET on the surface of tumor cells allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.1
EGFR, epidermal growth factor receptor; MET, Mesenchymal-Epithelial Transition.
Explore
Register for Updates
Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.
Reference
1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.